Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Helena W. Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, and Paul Norwood

1Endocrine and Metabolic Consultants, Rockville, Maryland 20852; 2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390; 3Endocrine Research Solutions, Inc., Roswell, Georgia 30076; 4Four Rivers Clinical Research, Paducah, Kentucky 42003; 5Institute of Diabetes Research, 48145 Münster, Germany; 6Cedar-Crosse Research Center, Chicago, Illinois 60607; 7Department of Metabolic Medicine, Kumamoto University, Kumamoto, 860-8555 Japan; 8Novo Nordisk Inc., Plainsboro, New Jersey 08536; 9Novo Nordisk A/S, 2860 Søborg, Denmark; and 10University of California at San Francisco, Fresno, California 93730

Context: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin.

Objective: To demonstrate the superiority of semaglutide vs placebo on glycemic control as an add-on to basal insulin in patients with T2D.

Design: Phase 3a, double-blind, placebo-controlled, 30-week trial.

Setting: This study included 90 sites in five countries.

Patients: We studied 397 patients with uncontrolled T2D receiving stable therapy with basal insulin with or without metformin.

Interventions: Subcutaneous semaglutide 0.5 or 1.0 mg once weekly or volume-matched placebo.

Main Outcome Measures: Primary endpoint was change in glycated Hb (HbA1c) from baseline to week 30. Confirmatory secondary endpoint was change in body weight from baseline to week 30.

Results: At week 30, mean HbA1c reductions [mean baseline value, 8.4% (67.9 mmol/mol)] with semaglutide 0.5 and 1.0 mg were 1.4% (15.8 mmol/mol) and 1.8% (20.2 mmol/mol) vs 0.1% (1.0 mmol/mol) with placebo [estimated treatment difference (ETD) vs placebo, –1.35 (14.8 mmol/mol); 95% CI, –1.61 to –1.10 and ETD, –1.75% (19.2 mmol/mol); 95% CI, –2.01 to –1.50; both P < 0.0001]. Severe or blood glucose–confirmed hypoglycemic episodes were reported in 11 patients (17 events) and 14 patients (25 events) with semaglutide 0.5 and 1.0 mg, respectively, vs seven patients (13 events) with placebo (estimated rate ratio vs placebo, 2.08; 95% CI, 0.67 to 6.51 and estimated rate ratio vs placebo, 2.41; 95% CI, 0.84 to 6.96 for 0.5 and 1.0 mg; both P = nonsignificant). Mean body weight decreased with semaglutide 0.5 and 1.0 mg vs placebo from baseline to end of treatment: 3.7, 6.4, and 1.4 kg (ETD, –2.31; 95% CI, –3.33 to –1.29 and ETD, –5.06; 95% CI, –6.08 to –4.04 kg; both P < 0.0001). Premature treatment discontinuation due to adverse events was higher for semaglutide 0.5 and 1.0 mg vs placebo (4.5%, 6.1%, and 0.8%), mainly due to gastrointestinal disorders.

Abbreviations: ADA, American Diabetes Association; AE, adverse event; bpm, beats per minute; DR, diabetic retinopathy; EAC, Event Adjudication Committee; ETD, estimated treatment difference; FPG, fasting plasma glucose; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated Hb; SF-36v2, 36-Item Short Form; SMBG, self-measured blood glucose; SUSTAIN, Semaglutide Unabated Sustained-ability in Treatment of Type 2 Diabetes; T2D, type 2 diabetes.

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution License (CC BY; https://creativecommons.org/licenses/by/4.0/).
Received 9 January 2018. Accepted 17 April 2018.
First Published Online 23 April 2018

doi: 10.1210/jc.2018-00070
J Clin Endocrinol Metab, June 2018, 103(6):2291–2301
https://academic.oup.com/jcem
Type 2 diabetes (T2D) is a complex disorder that requires individualized treatment strategies. Because of its progressive nature, many individuals receiving basal insulin require intensification of therapy to maintain optimal glycemic control and to reduce the risk of complications (1–5). Although increasing the basal insulin dose and/or adding mealtime insulin is often effective, this approach can increase the risk of hypoglycemia and lead to weight gain in an often overweight population (6).

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce blood glucose levels, with a low risk of hypoglycemia, and decrease body weight through reduced appetite and energy intake (7–9). Furthermore, GLP-1RAs in combination with basal insulin have been shown to reduce glycated Hb (HbA1c) and body weight, with a relatively low risk of hypoglycemia (10, 11). To improve treatment adherence and health-related quality of life for patients, recent efforts have focused on the development of once-weekly GLP-1RAs (12–14).

Semaglutide is a GLP-1 analog for the treatment of T2D. It has 94% amino acid sequence homology with native GLP-1 and is structurally similar to liraglutide (15, 16). Its minor structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and improve binding to albumin (15). These modifications result in a half-life of ~1 week (15), enabling once-weekly subcutaneous administration (17, 18).

The objective of this phase 3a, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) 5 trial was to demonstrate the superiority of once-weekly semaglutide (0.5 and 1.0 mg) vs placebo on glycemic control in patients with uncontrolled T2D on basal insulin therapy.

Materials and Methods

Trial design
This 30-week, randomized, double-blind, placebo-controlled, parallel-group, multinational, multicenter, four-armed trial (NCT02305381; Supplemental Fig. 1) recruited patients from 90 sites in Germany, Japan, Serbia, Slovakia, and the United States. The trial was conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines (19) and the Declaration of Helsinki (20). The protocol, which is available online, was approved by the relevant institutional review boards.

Patients
Eligible patients were ≥18 years of age (or ≥20 years of age in Japan) and diagnosed with T2D. All patients were receiving stable basal insulin therapy (minimum of 0.25 IU/kg/d and/or 20 IU/d of insulin glargine, insulin detemir, insulin degludec, and/or neutral protamine Hagedorn insulin) alone or in combination with metformin for 90 days prior to screening, with an HbA1c level of 7.0% to 10.0% (53.0 to 85.8 mmol/mol). Key exclusion criteria included treatment with any glucose-lowering agent other than those listed herein in the 90 days prior to screening (excepting short-term bolus insulin therapy of ≤7 days); history of pancreatitis (acute or chronic); family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m² according to the Modification of Diet in Renal Disease formula); more than three episodes of severe hypoglycemia within the 6 months prior to screening; known proliferative retinopathy or maculopathy requiring acute treatment; or being pregnant, breastfeeding, or intending to become pregnant. Full inclusion and exclusion criteria are listed in Supplemental Table 1. Written informed consent was obtained from all patients before trial-related activities commenced.

Randomization and masking
Patients were randomized using an interactive voice/web-response system in a 2:2:1:1 ratio to receive once-weekly semaglutide (0.5 or 1.0 mg subcutaneously) or placebo administered subcutaneously as an add-on to pretrial background medication. Semaglutide and placebo treatments were, as far as possible, visually identical and packaged in a way so that study patients and investigators would not be able to distinguish between trial products. Furthermore, semaglutide and placebo were volume-matched during treatment to ensure blinding within dose level. The randomization was stratified according to HbA1c level at screening (≤8.0% or >8.0%) and use of metformin (yes or no).

Background medication and basal insulin titration
Patients with HbA1c ≤8.0% (63.9 mmol/mol) at screening had their background basal insulin dose reduced by 20% at the start-of-trial medication to limit the potential risk of hypoglycemia. For these patients the insulin dose could be uptitrated from week 10 to week 16 (for further details, please see the titration protocol in the Supplemental Material). Increasing basal insulin dose before week 10 or after week 16 was avoided unless required to control acute hyperglycemia or prevent acute diabetic complications.

For all patients, insulin titrations were based on the lowest of three consecutive fasting self-measured blood glucose (SMBG) values according to a prespecified titration protocol (Supplemental Table 2). As far as possible, doses of basal insulin and metformin were to remain stable throughout the trial, with the exception of (1) dose reduction due to hypoglycemia or (2) confirmatory fasting plasma glucose (FPG) exceeding predefined limits per protocol, where the patient was offered intensification of therapy (rescue medication). Basal insulin dose increase was the first choice of rescue medication (Supplemental Material), which was initiated at the discretion of the investigator and in accordance with the American Diabetes
Drug administration

Patients received semaglutide (0.5 or 1.0 mg subcutaneously) or volume-matched placebo once weekly for 30 weeks followed by a 5-week follow-up period. Study medication was administered following a fixed dose-escalation regimen. For 0.5 mg, the maintenance dose was reached after 4 weeks of 0.25 mg semaglutide or matching placebo once weekly. For 1.0 mg, the maintenance dose was reached after 4 weeks of 0.25 mg, followed by 4 weeks of 0.5 mg semaglutide or matching placebo once weekly. Trial products were manufactured and supplied by Novo Nordisk A/S (Bagsvaerd, Denmark).

Outcomes

The primary outcome was the change in HbA1c from baseline to week 30. The confirmatory secondary endpoint was the change in body weight from baseline to week 30. Secondary efficacy endpoints included the proportion of patients who achieved HbA1c <7.0% (53 mmol/mol) (22) or ≤6.5% (48 mmol/mol) (23) by end of treatment; HbA1c <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemic episodes [plasma glucose level <3.1 mmol/L (56 mg/dL)] and no weight gain at week 30; change from baseline to week 30 in FPG; SMBG seven-point profiles and postprandial increments (mean over all meals); insulin dose; body mass index; waist circumference; proportion of patients who achieved weight loss of ≥5% and ≥10% at week 30; and change from baseline to week 30 of systolic and diastolic blood pressure, fasting lipids, and patient-reported outcomes [36-Item Short Form (SF-36v2) Health Survey and Diabetes Treatment Satisfaction Questionnaire].

Safety outcomes after 30 weeks of therapy included the number of treatment-emergent adverse events (AEs), severe or blood glucose–confirmed symptomatic hypoglycemic episodes (according to the ADA classification or blood glucose–confirmed by a plasma glucose value by end of treatment; HbA1c <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemic episodes [plasma glucose level <3.1 mmol/L (56 mg/dL)] and no weight gain at week 30; change from baseline to week 30 in FPG; SMBG seven-point profiles and postprandial increments (mean over all meals); insulin dose; body mass index; waist circumference; proportion of patients who achieved weight loss of ≥5% and ≥10% at week 30; and change from baseline to week 30 of systolic and diastolic blood pressure, fasting lipids, and patient-reported outcomes [36-Item Short Form (SF-36v2) Health Survey and Diabetes Treatment Satisfaction Questionnaire].

Safety outcomes after 30 weeks of therapy included the number of treatment-emergent adverse events (AEs), severe or blood glucose–confirmed symptomatic hypoglycemic episodes (according to the ADA classification or blood glucose–confirmed by a plasma glucose value <3.1 mmol/L with symptoms consistent with hypoglycemia), and pulse rate. Hypoglycemia was assessed as a secondary safety endpoint. When a hypoglycemic episode was suspected, the blood glucose level at the time of the event was recorded as well as additional information relating to the circumstances of the patient. A hypoglycemic episode form was completed for each hypoglycemic episode; if the episode fulfilled the criteria for a serious AE, then an AE form and a safety information form were also completed. Hypoglycemic episode forms were classified according to the Novo Nordisk A/S classification and ADA classification guidelines.

An external Event Adjudication Committee (EAC) validated predefined events of special interest [including those associated with GLP-1RA therapy: acute pancreatitis, neoplasm (excluding thyroid), and thyroid disease (including neoplasms)] in an independent, blinded manner (Supplemental Material).

Statistical analysis

The trial was designed to establish superiority jointly for both doses of semaglutide vs placebo (hereafter referred to as “placebo”) for the change in HbA1c and body weight at week 30 with a one-sided α of 2.5%, assuming treatment differences vs placebo of 0.45% and 2.25 kg for each semaglutide dose level, and SDs of 1.1% and 4.0 kg. The type I error probability was controlled at 2.5% (one-sided) across the four confirmatory superior hypotheses in a hierarchical testing strategy. For HbA1c, the superiority of semaglutide vs placebo was tested first, starting with the highest semaglutide dose level, followed by body weight superiority vs placebo in the same dose order. Based on these assumptions and on a target sample size of 390 patients in total, the overall power to simultaneously demonstrate superiority on change in HbA1c and body weight for the two dose levels of semaglutide vs placebo was 82% (full details are in Supplemental Material).

HbA1c, body weight, and other continuous endpoints assessed over time were analyzed using a mixed model for repeated measurements, with treatment, country, and stratification variables [HbA1c level at screening (≤8.0% or >8.0%) crossed with use of metformin (yes or no)] as fixed factors and baseline value as covariate, all nested within visit (full details are in Supplemental Material). Efficacy evaluations were based on the full analysis set, comprising all randomized patients exposed to at least one dose of trial product. The primary analyses used data collected before initiation of any rescue medication or before premature treatment discontinuation. The robustness of the analyses of HbA1c and body weight was assessed by handling missing data in various ways, including a placebo-based multiple imputation model, in which missing data points were imputed as if the patient was receiving placebo. Details of the sensitivity analyses are included in Supplemental Material.

Results

Patient disposition and baseline characteristics

In total, 397 patients were randomized to receive semaglutide or placebo from 1 December 2014 through 21 November 2015; 396 patients were exposed to treatment, and 380 patients completed the trial (Supplemental Fig. 2). A total of 23 patients required rescue medication: three in the semaglutide 0.5 mg group, one in the semaglutide 1.0 mg group, and 19 in the placebo group. Baseline characteristics were similar between treatment groups (Table 1). The mean duration of diabetes prior to trial entry was 13.3 years (range, 0.4 to 39.6 years). The majority of patients were receiving insulin glargine therapy at baseline (Table 1).

Glycemic control

Mean HbA1c [baseline 8.4%; SD, 0.83 (67.9 mmol/mol; SD, 9.04)] levels decreased over time (Fig. 1A; Supplemental Fig. 3A). At week 30, mean HbA1c values with semaglutide 0.5 and 1.0 mg were 6.9% and 6.5%, vs 8.3% with placebo, corresponding to reductions of 1.4% and 1.8% vs 0.1% with placebo [estimated treatment difference (ETD) vs placebo, −1.35% (95% CI, −1.61 to −1.10) and −1.75% (95% CI, −2.01 to −1.50; both P < 0.0001)]. The changes from baseline in HbA1c in patients with HbA1c ≤8% at screening were −0.88% (SD, 0.94), −1.32% (SD, 0.71), and −0.04% (SD, 0.98) with semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo, respectively, whereas in patients with HbA1c >8% the changes were −1.83% (SD, 1.00), −2.19% (SD, 0.86), and −0.28% (SD, 1.12), respectively.
| Table 1. Baseline Characteristics of the Study Population | Semaglutide 0.5 mg (n = 132) | Semaglutide 1.0 mg (n = 131) | Placebo (n = 133) | Total (N = 396) |
|----------------|-----------------------------|-----------------------------|------------------|-----------------|
| Male sex, n (%) | 74 (56.1)                   | 77 (58.8)                   | 71 (53.4)        | 222 (56.1)      |
| Country, n (%)  |                             |                             |                  |                 |
| Germany         | 25 (18.9)                   | 24 (18.3)                   | 21 (15.8)        | 70 (17.7)       |
| Japan           | 17 (12.9)                   | 22 (16.8)                   | 22 (16.5)        | 61 (15.4)       |
| Serbia          | 17 (12.9)                   | 13 (9.9)                    | 15 (11.3)        | 45 (11.4)       |
| Slovakia        | 13 (9.8)                    | 13 (9.9)                    | 14 (10.5)        | 40 (10.1)       |
| United States   | 60 (45.5)                   | 59 (45.0)                   | 61 (45.9)        | 180 (45.5)      |
| Race, n (%)     |                             |                             |                  |                 |
| White           | 108 (81.8)                  | 98 (74.8)                   | 101 (75.9)       | 307 (77.5)      |
| Asian           | 19 (14.4)                   | 23 (17.6)                   | 24 (18.0)        | 66 (16.7)       |
| Black or African American | 4 (3.0) | 9 (6.9) | 8 (6.0) | 21 (5.3) |
| Other           | 0 (0.0)                     | 1 (0.8)                     | 0 (0.0)          | 1 (0.3)         |
| Baseline HbA1c, n (%)a | 41 (3.1) | 41 (31.3) | 40 (30.1) | 122 (30.8) |
| ≤8.0% with metformin | 8 (6.1) | 8 (6.1) | 9 (6.8) | 25 (6.3) |
| >8.0% without metformin | 14 (10.6) | 13 (9.9) | 14 (10.5) | 41 (10.4) |
| Age, mean (min.–max.), y | 59.1 (28–84) | 58.5 (33–80) | 58.8 (19–86) | 58.8 (19–86) |
| HbA1c, mean (min.–max.), mmol/molb | 67.9 (53.0–89.1) | 67.3 (51.9–94.5) | 68.6 (50.8–97.8) | 67.9 (50.8–97.8) |
| HbA1c, mean (min.–max.), %c | 8.4 (7.0–10.3) | 8.3 (6.9–10.8) | 8.4 (6.8–11.1) | 8.4 (6.8–11.1) |
| Fasting plasma glucose, mean (min.–max.), mg/dL | 8.9 (2.9–21.9) | 8.5 (2.6–17.1) | 8.6 (3.9–19.1) | 8.6 (2.6–21.9) |
| Fasting plasma glucose, mean (min.–max.), mmol/L | 161.0 (52.3–394.6) | 152.5 (46.9–308.1) | 154.1 (70.3–344.2) | 155.9 (46.9–394.6) |
| Diabetes duration, mean (min.–max.), y | 12.9 (0.4–37.1) | 13.7 (0.6–36.9) | 13.3 (0.8–39.6) | 13.3 (0.4–39.6) |
| Body weight, mean (min.–max.), kg | 92.7 (50.4–162.8) | 92.5 (48.5–165.6) | 89.9 (47.5–157.3) | 91.7 (47.5–165.6) |
| Body mass index, mean (min.–max.), kg/m2  | 32.8 (21.1–51.4) | 32.0 (19.5–51.6) | 31.8 (21.0–48.8) | 32.2 (19.5–51.6) |
| Basal insulin dose, mean (min.–max.), IU | 39.3 (15.0–300.0) | 37.4 (14.0–320.0) | 36.6 (12.0–124.0) | 37.7 (12.0–320.0) |
| Insulin glargine | 42.6 (15.0–100.0) | 50.3 (14.0–320.0) | 43.4 (15.0–124.0) | 45.4 (14.0–320.0) |
| Insulin detemir | 56.1 (28.0–120.0) | 40.1 (20.0–130.0) | 40.0 (15.0–100.0) | 44.3 (15.0–130.0) |
| Insulin degludec | 63.8 (22.0–300.0) | 30.3 (20.0–67.0) | 35.5 (12.0–60.0) | 39.8 (12.0–300.0) |
| NPH insulin | 46.0 (20.0–130.0) | 40.4 (20.0–80.0) | 45.5 (20.0–124.0) | 44.5 (20.0–130.0) |
| Oral diabetes medication, n (%) | 110 (83.3) | 110 (84.0) | 110 (82.7) | 330 (83.3) |
| Metformin | – | – | 1 (0.8) | 1 (0.3) |
| Sulfonylureas | – | – | – | – |
| Basal insulin at baseline, n (%) | 76 (57.6) | 70 (53.4) | 67 (50.4) | 213 (53.8) |
| Insulin glargine | 20 (15.2) | 27 (20.6) | 28 (21.1) | 75 (18.9) |
| Insulin detemir | 10 (7.6) | 19 (14.5) | 14 (10.5) | 43 (10.9) |
| Insulin degludec | 27 (20.5) | 15 (11.5) | 24 (18.0) | 66 (16.7) |

Abbreviations: IU, international unit; max., maximum; min., minimum; NPH, neutral protamine Hagedorn; y, years.

aRandomization was stratified according to HbA1c level at screening (≤8.0% or >8.0%) and use of metformin (yes or no).
bHbA1c may be outside the range specified in the inclusion criteria because baseline measurement was conducted at randomization visit.
cThis patient was randomized in error and consequently excluded from the trial.

Significantly more patients achieved an HbA1c target of <7.0% with semaglutide 0.5 mg and 1.0 mg than with placebo (61%, 79%, and 11%) (Fig. 2A) and an HbA1c target ≥6.5% with semaglutide 0.5 and 1.0 mg vs placebo (41%, 61%, and 5%) (Supplemental Fig. 4A). Significantly more patients achieved a composite endpoint of <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemia and with no weight gain with semaglutide 0.5 and 1.0 mg compared with placebo (54%, 67%, and 7%) (Fig. 3).

At week 30, mean FPG values with semaglutide 0.5 and 1.0 mg were 7.0 and 6.3 mmol/L vs 8.2 mmol/L with placebo, corresponding to decreases of 1.6 and 2.4 mmol/L, compared with 0.5 mmol/L with placebo (ETD, −1.14; 95% CI, −1.75 to −0.54 and ETD, −1.88; 95% CI, −2.48 to −1.28; both P < 0.001) (Fig. 1B; Supplemental Table 3). Both incremental and mean seven-point SMBG decreased significantly with semaglutide 0.5 mg (by 0.8 and 2.5 mmol/L; both P < 0.004) and 1.0 mg (by 1.2 and 3.0 mmol/L; P < 0.0001 for both) vs placebo (reductions of 0.2 and 0.8 mmol/L) (Fig. 4; Supplemental Table 3).

Severe or blood glucose–confirmed hypoglycemic episodes were reported in 11 (8.3%) patients (17 events) in the semaglutide 0.5 mg group, in 14 (10.7%) patients (25 events) in the semaglutide 1.0 mg group, and in...
7 (5.3%) patients (13 events) in the placebo group. The estimated rate ratio for events of severe or blood glucose–confirmed hypoglycemia was 2.08 (95% CI, 0.67 to 6.51; $P = 0.2071$) for semaglutide 0.5 mg vs placebo and 2.41 (95% CI, 0.84 to 6.96; $P = 0.1030$) for semaglutide 1.0 mg vs placebo. Among patients with HbA$_1c$ $\leq$ 8.0% at screening,
the proportion of patients reporting these events was higher in both semaglutide groups vs the placebo group and highest in the higher-dose semaglutide group (15.7, 46.5, and 9.9 events per 100 patient-years of exposure for semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo, respectively). In subjects with HbA1c >8%, the rates of “severe or BG-confirmed symptomatic” hypoglycemic episodes were comparable among the three groups (22.9, 21.2, and 18.6 events per 100 patient-years of exposure for semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo, respectively) (Fig. 1D; Supplemental Table 5; Supplemental Fig. 8).

**Insulin dose**

Insulin dose decreased from baseline to week 30 with semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo (geometric means from 39.3 to 35.4, from 37.4 to 31.5, and from 36.6 to 35.2 IU). The end-of-treatment to baseline ratio for insulin dose with semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo was 0.90, 0.85, and 0.96 (estimated treatment ratio for semaglutide 0.5 mg and 1.0 mg vs placebo, 0.94; 95% CI, 0.90 to 0.98 and estimated treatment ratio, 0.88; 95% CI, 0.84 to 0.92; \( P = 0.0046 \) and \( P < 0.0001 \)). The largest overall decrease in insulin dose was in patients with baseline HbA1c <8.0%. These patients reduced their insulin dose by 20% at randomization, in accordance with protocol (Supplemental Fig. 5).

**Body weight and related endpoints**

At week 30, mean body weight decreased with semaglutide 0.5 and 1.0 mg vs placebo by 3.7, 6.4, and 1.4 kg (ETD for semaglutide 0.5 mg and 1.0 mg vs placebo, −2.31; 95% CI, −3.33 to −1.29 and ETD, −5.06; 95% CI, −6.08 to −4.04; both \( P < 0.0001 \)) (Fig. 1C; Supplemental Fig. 3B). Body weight reductions of ≥5% were achieved in the semaglutide 0.5 mg, semaglutide 1.0 mg, and placebo groups by 42%, 66%, and 11% of patients and reductions of ≥10% by 9%, 26%, and 3% (Fig. 2B; Supplemental Fig. 4B).

**Other efficacy endpoints**

Improvements in other efficacy endpoints, including lipid profile and systolic blood pressure, were observed with semaglutide vs placebo (Supplemental Tables 3 and 4). At week 30, mean systolic blood pressure values were 130.5 and 127.5 mm Hg for semaglutide 0.5 mg and 1.0 mg vs 133.8 mm Hg for placebo (ETD, −3.31; 95% CI, −6.92 to 0.31 and ETD, −6.29; 95% CI, −9.91 to −2.66; \( P = 0.0728 \) and \( P = 0.0007 \)). Overall treatment satisfaction (measured by the Diabetes Treatment Satisfaction Questionnaire, status version) significantly improved with both semaglutide doses vs placebo (0.5 mg: ETD, 1.48; 95% CI, 0.14 to 2.82 and 1.0 mg: ETD, 2.22; 95% CI, 0.87 to 3.56) (Supplemental Fig. 6). No significant changes were evident from the SF-36v2 Health Survey questionnaire with either semaglutide dose compared with placebo.

**Safety and tolerability**

The proportions of patients with AEs and serious AEs for semaglutide 0.5 and 1.0 mg vs placebo were 68.9%, 64.1%, and 57.9% and 61%, 9.2%, and 6.8% (Table 2). Rates of premature treatment discontinuation due to AEs were generally low but were higher with
semaglutide 0.5 and 1.0 mg vs placebo (4.5% and 6.1% compared with 0.8% in the placebo group) and were primarily due to gastrointestinal (GI) AEs (Table 2).

No fatalities were reported during the trial. One patient receiving semaglutide 0.5 mg became pregnant during the trial and discontinued treatment after 106 days (fetal exposure was ∼9 weeks). A healthy baby was born with no known congenital abnormalities.

The most frequent AEs with semaglutide were GI AEs (Table 2). Nausea was reported in 11.4% of patients treated with semaglutide 0.5 mg and in 16.8% treated with semaglutide 1.0 mg compared with 4.5% receiving placebo. In general, the prevalence of nausea events over time with semaglutide treatment was ∼3% to 5% throughout the study (Supplemental Fig. 7A). The proportions of patients reporting vomiting were 6.1%, 11.5%, and 3.0% (the prevalence of vomiting events over time is shown in Supplemental Fig. 7B), and the proportions reporting diarrhea were 4.5%, 6.9%, and 1.5%. All GI AEs were mild to moderate in severity. Pulse rate increased from baseline by 1 beat per minute (bpm) with semaglutide 0.5 mg and by 4 bpm with semaglutide 1.0 mg, vs a decrease of 1 bpm with placebo (for semaglutide 1.0 mg vs placebo, \( P < 0.0001 \); Supplemental Table 3). The proportion of patients with diabetic retinopathy (DR) events was 3.0% with semaglutide 0.5 mg and 0.8% with semaglutide 1.0 mg; there were no patients with DR events on placebo.

Gallbladder-related AEs were reported in four semaglutide-treated patients. With semaglutide 0.5 mg, cholelithiasis, gallbladder disorder, and blood alkaline phosphatase were reported in three patients; with semaglutide 1.0 mg, acute cholecystitis was reported in one patient (Table 2). Mean lipase and amylase activity increased significantly from baseline to end of treatment with both semaglutide doses compared with placebo (\( P < 0.0001 \) for all) (Supplemental Table 6; Supplemental Fig. 9), although no pancreatitis events were confirmed by the EAC. Two investigator-reported events were sent for

**Figure 3.** Patients achieving the composite endpoint target of HbA\(_1c\) <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemia and with no weight gain. Values are observed proportions using “on-treatment without rescue medication” data from patients in the full analysis set. Missing HbA\(_1c\) and body weight data were imputed from a mixed model for repeated measurements analysis and subsequently classified. “Blood glucose–confirmed” defined as blood glucose <3.1 mmol/L (56 mg/dL). Values in square brackets indicate 95% CIs. *Significant at \( P < 0.0001 \). EOR, estimated OR.

---

**Figure 4.** Observed mean seven-point self-measured blood glucose profile at baseline and at week 30. Values are observed means based on “on-treatment without rescue medication” data from patients in the full analysis set. Dashed lines represent week 0 data; solid lines represent week 30 data.
adjudication: one patient (female, age 47 years) receiving semaglutide 0.5 mg reported acute pancreatitis, which led to premature treatment discontinuation (reported on study day 152, concurrent mild vomiting); the second patient (male, age 55 years) receiving semaglutide 1.0 mg reported elevated lipase but had an elevated level prior to administration of trial product (reported on study day 1, concurrent mild vomiting).

Neoplasms were confirmed by the EAC in four patients treated with semaglutide 0.5 mg and in one patient receiving placebo (Table 2). One malignant neoplasm (basal cell carcinoma) was reported in a patient treated with semaglutide 1.0 mg. Additionally, one patient treated with semaglutide 1.0 mg had confirmed metastatic pancreatic cancer with an onset date of 65 days after the end of treatment. There were no confirmed thyroid malignancies.

### Discussion

In patients with T2D inadequately controlled with basal insulin, semaglutide provided superior improvements in mean HbA1c, FPG, and SMBG and superior weight loss compared with placebo. There was a low rate of hypoglycemic episodes across the trial. Compared with placebo, severe or blood glucose–confirmed symptomatic episodes were more frequent with semaglutide in patients with HbA1c ≥8.0% at screening, which might be expected given the improvements in HbA1c in these patients vs placebo. A greater pre-emptive insulin dose reduction, greater than the 20% mandated by the protocol in this trial, may be appropriate when titrating from 0.5 to 1.0 mg in clinical practice.

In this study population with a mean diabetes duration of >13 years, the majority of patients in both semaglutide-treatment groups attained an HbA1c target of <7.0%. In addition, significant weight loss was observed with both doses of semaglutide vs placebo. The improvements (weight reductions of 2.3 to 5.1 kg) with semaglutide appear to be greater in magnitude than those previously reported for other long-acting GLP-1RAs added to basal insulin (weight reductions of 1.0 to 1.6 kg), although these are cross-trial observations and therefore are not directly comparable (8, 24–29).

A significantly larger proportion of patients receiving semaglutide achieved the composite endpoint of HbA1c <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemia (plasma glucose level below

### Table 2. Adverse Events Overview

|                      | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo |
|----------------------|-------------------|-------------------|---------|
| n (%) Events (n)     | n (%) Events (n)  | n (%) Events (n)  |         |
| No. of patients      | 132 (68.9)        | 131 (64.1)        | 77 (57.9) |
| AEs (total)          | 91 (6.1)          | 84 (6.1)          | 0       |
| Fatal                | 5 (3.8)           | 10 (7.6)          | 6 (4.5) |
| Serious              | 8 (6.1)           | 12 (9.2)          | 9 (6.8) |
| Severitya            | 42 (31.8)         | 32 (24.4)         | 28 (21.1) |
| Severe               | 68 (51.9)         | 174 (138)         | 64 (48.1) |
| Moderate             | 6 (4.5)           | 8 (6.1)           | 1 (0.8) |
| Mild                 | 218 (164)         | 174 (138)         | 158 (120) |
| Leading to premature treatment discontinuation | | | |
| GI AEs               | 6 (4.5)           | 8 (6.1)           | 1 (0.8) |
| Nausea               | 15 (11.4)         | 22 (16.8)         | 6 (4.5) |
| Vomiting             | 8 (6.1)           | 15 (11.5)         | 4 (3.0) |
| Diarrhea             | 6 (4.5)           | 9 (6.9)           | 2 (1.5) |
| Severe or BG-confirmed symptomatic hypoglycemia | | | |
| Cardiovascular AEs   | 12 (9.1)          | 7 (5.3)           | 8 (6.0) |
| Gallbladder-related AEs | 3 (2.3)      | 1 (0.8)           | 0       |
| EAC-confirmed neoplasmsb | 4 (3.0) | 0 (0.8)           | 1 (0.8) |
| Benign               | 4 (3.0)           | 1 (0.8)           | 1 (0.8) |
| Colorectal           | 2 (1.5)           | 2 (1.5)           | 0       |
| Skin                 | 1 (0.8)           | 1 (0.8)           | 0       |
| Nasopharyngeal       | 1 (0.8)           | 1 (0.8)           | 0       |
| Malignant            | 1 (0.8)           | 1 (0.8)           | 0       |
| Skin                 | 1 (0.8)           | 1 (0.8)           | 0       |

Abbreviations: AE, adverse event; BG, blood glucose; EAC, Event Adjudication Committee; GI, gastrointestinal.

aSevere, considerable interference with the subject’s daily activities, unacceptable; moderate, marked symptoms, moderate interference with the subject’s daily activities; mild, no or transient symptoms, no interference with the subject’s daily activities.

bThere were five events in four patients with semaglutide 0.5 mg.
3.1 mmol/L) and without weight gain compared with placebo. This finding is clinically meaningful and especially promising in a population where hypoglycemia and weight gain impede insulin titration and glycemic control.

Semaglutide was well tolerated in this trial, with an AE profile similar to that of other GLP-1RAs. GI symptoms were the most common AEs with semaglutide and were responsible for the higher proportion of patients discontinuing treatment prematurely compared with placebo. This effect has been noted previously with GLP-1RAs, and GI AEs commonly occur early in the course of treatment and subside over time (30). Accordingly, in this study, nausea events in the semaglutide groups occurred mainly in the first 8 to 9 weeks of treatment, generally coinciding with the dose-escalation steps, and declined gradually thereafter until the end of the trial. Although the proportion of patients experiencing an event at least once was ~11% to 17% with semaglutide, the actual prevalence was ~3% to 5% on any given week. The prevalence of vomiting over time remained ≤2.5% in both semaglutide groups, and the majority of events occurred before week 18 of the study.

Similarly, the significant increase in pulse rate observed with semaglutide 1.0 mg compared with placebo has been previously reported in patients treated with GLP-1RAs (31, 32); however, the reasons for this hemodynamic effect are unclear (33). DR AEs in SUSTAIN 5 are discussed in a publication that analyzes DR in the SUSTAIN clinical program. An analysis of DR AEs in SUSTAIN 1–5 and the Japanese trials showed no evidence of increased DR AEs with semaglutide vs placebo or active comparators (34). One malignant neoplasm (basal cell carcinoma) was reported in the study in a patient treated with semaglutide 1.0 mg. In the same treatment group, one patient had metastatic pancreatic cancer, although the recorded date of onset was 65 days after the end of treatment. In published data from the SUSTAIN program, the overall incidence of malignant neoplasms was similarly low, with no evident imbalances between semaglutide dose groups or between semaglutide and comparators (35–37). No pancreatitis events were confirmed by the EAC, a finding that aligns with a recent meta-analysis of incretin-based medications and the reported risk of such events (38). In the analysis, which included results from the SUSTAIN 6 trial (39), the relative risk of both acute pancreatitis and pancreatic carcinoma was reduced for semaglutide and the GLP-1RA class overall (38).

Semaglutide treatment was associated with improvements in treatment satisfaction compared with placebo. However, despite the double-blind study design, the substantial differences in efficacy (e.g., weight loss) and safety (e.g., GI AEs) between semaglutide and placebo may have unblinded the study in many patients by week 30, thereby affecting the patient’s evaluation of the treatment. Nevertheless, therapies demonstrating increased treatment satisfaction in T2D could be beneficial, particularly because insulin therapy for diabetes is associated with a high treatment burden and compliance issues (40).

The strengths of this study include its randomized, double-blind, placebo-controlled design, which adds validity to the evaluation of outcomes. The trial was conducted in patients with long-standing T2D who were receiving basal insulin, and, although the majority was receiving insulin glargine therapy at baseline, a diverse range of insulin types was used, reflecting the international nature of the trial sites in this study.

This was not a treat-to-target study; thus, titration was carried out at the investigators’ discretion, with the exception of the mandatory dose decrease in patients with HbA1c ≤8%. The lack of dose up titration in the placebo arm may have been partially responsible for HbA1c and FPG levels remaining elevated in this treatment group. Furthermore, because basal insulin was not titrated to target and because the placebo arm had no active intervention, the comparison of hypoglycemia rates between the arms and the applicability of the study findings to clinical practice should be interpreted according to these limitations.

The relatively short study length was a limitation, and the binding aspect of the trial may have been partially lost due to the incidence of GI AEs and the improved fasting glucose levels over placebo. Because of the reduced insulin dose in the cohort with HbA1c ≤8% and the subsequent delay before uptitration could be commenced, the results relating to weight loss and reduced insulin requirements should be interpreted in this context. In addition, the observed decrease in insulin dose and in body weight in the placebo group was unexpected, and the reasons for these anomalous effects are unclear.

In summary, semaglutide, administered subcutaneously once weekly, provided superior glycemic control and body weight reductions compared with placebo in patients with T2D receiving basal insulin therapy. No unexpected safety issues were identified. Semaglutide was well tolerated, with a safety profile similar to that of other GLP-1RAs.

Acknowledgments

We thank the patients, investigators, and trial-site staff who were involved in the trial; Louise Faerch, Uffe Ploug, and Desirée Thielke (all Novo Nordisk employees) for their review of and input to the manuscript; and Madeleine Nowak (AXON Communications) for medical writing and editorial assistance. Key findings from this study were presented in abstract form at the
52nd EASD Annual Meeting, Munich, Germany, 12–16 September 2016.

Financial Support: This study was funded by Novo Nordisk A/S.

Clinical Trial Information: SUSTAIN 5 ClinicalTrials.gov no. NCT02305381 (registered 28 November 2014).

Author Contributions: All authors were site investigators, except those employed by Novo Nordisk, and took part in the conduct of the trial and the data collection. The data were analyzed by the statistical group. H.W.R. served as a Principal Investigator, researched the data, reviewed and edited the manuscript, and contributed to the discussion. I.L. researched the data, reviewed and edited the manuscript, and contributed to the discussion. J.R. reviewed and edited the manuscript and contributed to the discussion. R.d.l.R. reviewed and edited the manuscript and contributed to the discussion. P.N. researched the data, reviewed and edited the manuscript, and contributed to the discussion. P.-L.C. researched the data, reviewed and edited the manuscript, and contributed to the discussion. L.R. reviewed and edited the manuscript and contributed to the discussion. D.S. reviewed and edited the manuscript. E.A. reviewed and edited the manuscript and contributed to the discussion. P.-L.C. researched the data, reviewed and edited the manuscript, and contributed to the discussion. N.W. researched the data, wrote the manuscript, reviewed and edited the manuscript, and contributed to the discussion. P.N. researched the data, reviewed and edited the manuscript, and contributed to the discussion. All the authors have read the report critically and approved the submitted version, and all authors take responsibility for the contents of the article.

Correspondence and Reprint Requests: Helena W. Rodbard, MD, 3200 Tower Oaks Boulevard, Suite 250, Rockville, Maryland 20852. E-mail: hrodbard@comcast.net.

Disclosure Summary: H.W.R. has received grant support and fees for consultancy from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk and Sanofi. I.L. has received grant support from Gl Dynamics, Merck, Novartis, Novo Nordisk, and Pfizer; travel and editorial support from Novo Nordisk; and editorial support from AstraZeneca, Boehringer Ingelheim, and Sanofi. J.R. has received research support from Novo Nordisk; Eli Lilly; Sanofi; Takeda; Bristol Myers Squibb; Diasome; Gann & Lee; Kowa; Calibra Medical, Inc.; Amylin, Medtronic; ELSAI; Biodel; Johnson & Johnson; Amgen; Wyeth; Novartis; Dexcel; and Pfizer. R.d.l.R. has received grant support, speaker fees, and medical writing support from Novo Nordisk; grant support and speaker fees from Sanofi Aventis; speaker fees from Boehringer Ingelheim; and grant support from Amylin, Eccelyx Therapeutics, GlaxoSmithKline, Intarcia Therapeutics, Merck, and Theracos. D.S. has received grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eccelyx Therapeutics, Ligand Pharmaceuticals, Merck, Novo Nordisk, Roche, Sanofi, and Takeda and has received medical writing support from Novo Nordisk and Sanofi. L.R. has received grants and personal fees from AstraZeneca, Lilly, and Novo Nordisk. E.A. has received research support or grants and/or personal fees for lecturing and consulting on advisory boards and has received editorial support from Arkray, Inc.; Astellas Pharma, Inc.; AstraZeneca KK; Bayer Yakuhin Ltd; Bunkodo Co. Ltd; Daiido Gakkkan; Daiichi Sankyo; Eli Lilly Japan KK; Kissei Pharmaceutical Co.; Kowa Pharmaceutical Co. Ltd; Kyowa Hakko Kirin Co. Ltd; Kyowa Kikaku Ltd; Medical Review Co. Ltd; Mochida Pharmaceutical Co. Ltd.; Mitsubishi Tanabe Pharma Corporation; MSD; Nankodo Co. Ltd; Nippon Boehringer Ingelheim; Novartis Pharma KK; Novo Nordisk; Ono Pharmaceutical; Sanofi KK; Sanwa Kagaku Kenkyusho Co.; Shionogi & Co. Ltd; Sumitomo Dainippon Pharma Co.; Taisho Toyama Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Company; T-Pec Corporation; and Wiley Publishing Japan Co. Ltd. P.-L.C. reports being an employee of Novo Nordisk Inc. while the trial was conducted. N.W. reports being an employee of Novo Nordisk A/S. P.N. reports receiving research support from Novo Nordisk.

References

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.

2. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314–322.

3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.

4. Okubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117.

5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.

6. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S253–S259.

7. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15–27.

8. Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10(6):e0126769.

9. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–520.

10. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112.

11. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112.

12. Samson SL, Garber AJ. A plethora of GLP-1 agonists: decisions about what to use and when. Curr Diab Rep. 2016;16(12):120.

13. Madsbad S. A review of head-to-head comparisons of GLP-1 receptor agonists. Diabetes Obes Metab. 2015;18(4):317–322.

14. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144–149.
15. Lau J, Bloch P, Schaffer I, Pettersson I, Spetzer J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Redditz-Runge S, Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *J Med Chem.* 2015; 58(18):7370–7380.

16. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists: available efficacy and safety data and perspectives for the future. *Diabetes Obes Metab.* 2011; 13(5):394–407.

17. Kapitza C, Nosek I, Jensen L, Hartvig H, Jensen CB, Flint A. Efficacy and safety of exenatide in Japanese patients with type 2 diabetes (DURATION-3): a 26-week double-blind study. *Diabetes Care.* 2012; 35(2):252–258.

18. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González-JG, Chan M, Wolka AM, Boordman MK; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. *Diabetes Care.* 2012; 35(2):252–258.

19. Buse JB, Nauck M, Forst T, Torekov SS, Holst JJ. The bioavailability of the combined oral contraceptive, ethinyles-tradiol/levonorgestrel. *J Clin Pharmacol.* 2015; 55(5):497–504.

20. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González-JG, Chan M, Wolka AM, Boordman MK; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-3): a randomized controlled trial (AWARD-3). *Diabetes Care.* 2014; 37(8):2168–2176.

21. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Yej J, Scott R, Johnson S, Rosenstock J, de la Peña A, Teng CH, Calogéri S; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding non-insulin analogues or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med.* 2009; 26(3):268–278.

22. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013; 310(20):2191–2194.

23. Semaglutide, a once-weekly GLP-1 receptor agonist, does not reduce glycated haemoglobin and the risk of diabetic retinopathy, and is safe and well tolerated in Japanese patients with type 2 diabetes mellitus. *J Clin Pharmacol.* 2008; 48(12):1389–1399.

24. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013; 310(20):2191–2194.

25. European Medicines Agency. Guideline for good clinical practice (E6 (R2)). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed April 2018.

26. Rodbard HW, Blonde I, Brinthaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovannis LG, Levy P, Mechanich JJ, Zangeneh F. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract.* 2007; 13(Suppl 1):1–68.

27. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, O’Malley F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. *Lancet Diabetes Endocrinol.* 2015; 3(2):289–297.

28. Distribution of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013; 310(20):2191–2194.

29. European Medicines Agency. Guideline for good clinical practice (E6 (R2)). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed April 2018.

30. European Medicines Agency. Guideline for good clinical practice (E6 (R2)). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed April 2018.

31. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013; 310(20):2191–2194.